Computed Tomography

Cardiac computed tomography (CT) has become a primary cardiovascular imaging modality in the past 20 years, and was recommended as a 1A recommendation in the 2021 chest pain assessment guidelines. CT calcium scoring has became a primary risk assessment for coronary artery disease and whether patients should be on statins. Coronary CT angiography (CCTA) is used to for anatomical assessment of the arteries for plaque burden and to identify areas of blockage that may cause ischemia and heart attacks. Additional use of contrast CT perfusion or fractional flow reserve CT (FFR-CT) can offer physiological information on the function of the heart. CT plays a primary role in structural heart assessments for heart valves, repair of congenital defects and left atrial appendage occlusion (LAAO) for both pre-procedure planning and procedural guidance. Find more news on general radiology CT use.

How to take your CCTA program to the next level
Changing society guidelines and insurance policies have resulted in more interest in CCTA. To help your CCTA program expand, one expert told Cardiovascular Business, it is important to remember the close relationship between cardiology and radiology.
FDA clears next-generation platform for AI-powered heart assessments
An updated version of Heartflow's Plaque Analysis platform has gained FDA clearance. In addition, the company announced that Cigna will cover the platform going forward.
Cardiologist Carlos Collet takes new leadership role with CRF
Collet, known globally for his dedication to innovation, is the organization's new director of cardiovascular imaging, physiology and translational therapeutics.
FDA clears GE Revolution Vibe CT scanner aimed at rapidly growing CCTA market
“FDA clearance comes at the perfect time, with guidelines being adopted clinically for cardiac CT and with positive reimbursement driving procedure growth," says Jean-Luc Procaccini, CEO, molecular imaging and CT.
How to address CCTA staffing shortages
Jaime Warren, EdD, FACC, vice president of care transformation at MedAxiom, an ACC company, explains what is needed to address staffing shortages created by a 94% increase in cardiac CT volumes over the past 5 years.

Jaime Warren, EdD, MBA, BHS, CNMT, NCT, FACC, vice president, care transformation, MedAxiom, an ACC company, explains some of the things centers should be thinking about when creating or expanding cardiac CT angiography (CCTA) programs.

How to take your CCTA program to the next level

Changing society guidelines and insurance policies have resulted in more interest in CCTA. To help your CCTA program expand, one expert told Cardiovascular Business, it is important to remember the close relationship between cardiology and radiology.

FDA clears next-generation platform for AI-powered heart assessments

An updated version of Heartflow's Plaque Analysis platform has gained FDA clearance. In addition, the company announced that Cigna will cover the platform going forward.

Cardiologist Carlos Collet takes new leadership role with CRF

Collet, known globally for his dedication to innovation, is the organization's new director of cardiovascular imaging, physiology and translational therapeutics.

FDA clears GE Revolution Vibe CT scanner aimed at rapidly growing CCTA market

“FDA clearance comes at the perfect time, with guidelines being adopted clinically for cardiac CT and with positive reimbursement driving procedure growth," says Jean-Luc Procaccini, CEO, molecular imaging and CT.

How to address CCTA staffing shortages

Jaime Warren, EdD, FACC, vice president of care transformation at MedAxiom, an ACC company, explains what is needed to address staffing shortages created by a 94% increase in cardiac CT volumes over the past 5 years.

Positron NeuSight PET-CT 64 slice scanner

Nuclear imaging company Positron moves to New York for ‘exciting new chapter’

Positron made the move to help its case when it files an official Form 10 registration statement with the SEC.

Australia-based Artrya Limited said its Salix Coronary Plaque module AI-powered cloud platform offers near-real time, point-of-care CCTA assessment and management of coronary artery disease.

FDA clears CCTA AI coronary plaque assessment from Artrya

Australia-based Artrya Limited says its AI-enabled Salix Coronary Plaque module offers near real-time, point-of-care CCTA assessment and management of coronary artery disease.

Heartflow president and CEO John Farquhar celebrate the company's IPO by ringing Nasdaq's the ceremonial opening bell.

Heartflow raises $364M with IPO, rings Nasdaq opening bell

Heartflow has officially gone public after selling more than 19 million shares of common stock during an upsized IPO. The California medtech company, known for its AI-powered CCTA evaluations, is now being traded on Nasdaq under the symbol HTFL.